OrthoPediatrics corp Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)0.98 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $21.69Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $566.3M Enterprise Value $651.3M Shares Outstanding 24M diluted Next Earnings Date28 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary OrthoPediatrics Corp. (NASDAQ: KIDS) is a highly specialized, pure-play pediatric orthopedic device company addressing an underserved global market. The company's unique focus on children's hospitals and pediatric surgeons creates high switching costs and strong brand loyalty. With the recent EU MDR approval enabling a return to European product launches, direct sales expansion in Brazil, and positive momentum in adjusted EBITDA, OrthoPediatrics is well-positioned to transition toward sustainable profitability and cash flow self-sufficiency by late 2026. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$20.00 Mean target$25.00 High · most bullish analyst$34.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Sales representative attrition, delays in capital sales (such as 7D technology), or supply chain disruptions for specialized implant components slow down top-line growth to high single digits. Continued heavy capital expenditure on consigned implant sets delays the timeline to positive free cash flow, depressing the valuation multiple. Base CaseCentral scenario The company successfully executes on its 2026 revenue guidance of $262M to $266M (representing 11% to 13% growth) and achieves its target of approximately $25M in Adjusted EBITDA. Growth is driven by the continued ramp of the 3P Platform, scoliosis systems, and specialty bracing (OPSB), alongside international expansion. Operating leverage improves as set deployment costs normalize. Bull CaseUpside scenario The bull case centers on OrthoPediatrics' dominant position in the underserved pediatric orthopedic niche, driving consistent double-digit revenue growth (11-13% projected for FY2026). Key growth drivers include the rapid scaling of the OrthoPediatrics Specialty Bracing (OPSB) business, a multi-year new product launch cycle (such as DF2 and the 3P platform) driving higher average selling prices, and robust international expansion (22% growth in Q1 2026). High gross margins (~73%) provide strong operating leverage, positioning the company to achieve free cash flow breakeven in 2026 and transition toward sustainable profitability. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |